In 2019 we set up our first Scientific Advisory Board to help assess the requests we receive for funding research projects. We are honoured to have exceptional experts in the area of neuroblastoma. With their expertise, we will be able to ensure we fund the most promising meaningful research in line with our mission; developing better, safer and kinder treatments so all children diagnosed with neuroblastoma get the chance to grow up and lead a long and healthy life.
Prof Andy Pearson is formerly a Cancer Research UK Professor of Paediatric Oncology, at the Institute of Cancer Research and the Royal Marsden Hospital NHS Trust. During a long and distinguished career, he helped establish and led many key groups in the paediatric oncology landscape both nationally and internationally.
Dr. DuBois is director of experimental therapeutics at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center. He is a pediatric oncologist with an active clinical and translational research program focused on patients with advanced neuroblastoma and Ewing sarcoma. He conducts phase 1 and 2 clinical trials of novel targeted agents. His clinical practice focuses on providing outstanding team-based care for children and young adults with solid cancers.
Dr. Juliet Gray is an Associate Professor in Paediatric Oncology at the Cancer Immunology Centre, University of Southampton. She leads a translational research group focused on novel antibody immunotherapies for neuroblastoma, including preclinical evaluation of novel combinational therapies as well as early phase clinical trials.